BCM
ALBO

Bayesian Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

Bayesian Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-343
Closed -$4K – 460
2015
Q4 		$4K Buy
+343
New +$3.55K 0.01% 234

Other funds holding ALBO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bayesian Capital Management's ALBO Position: Q1 2016 in Review

Bayesian Capital Management sold out of Albireo Pharma Inc (ALBO) in Q1 2016, closing a stake of 343 shares — an estimated $4K sold.

Bayesian Capital Management first reported a position in ALBO in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 29 funds tracked by Wall St. Rank hold ALBO as of Q1 2016.

  • Bayesian Capital Management reported no remaining Albireo Pharma Inc position as of Q1 2016 after selling out during the quarter.
  • Bayesian Capital Management sold 343 Albireo Pharma Inc shares in Q1 2016, an estimated $4K.
  • Bayesian Capital Management first reported a position in Albireo Pharma Inc in Q4 2015 and held it in 1 quarter.
  • Bayesian Capital Management's Albireo Pharma Inc position peaked at $4K in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2016.

Based on Bayesian Capital Management's 13F filing for Q1 2016, filed 16 May 2016.